wild-type ATTR amyloidosis

GPTKB entity

Statements (50)
Predicate Object
gptkbp:instanceOf gptkb:disease
gptkbp:affects gptkb:nervous_system
gptkb:carpal_tunnel
heart
gptkbp:alsoKnownAs gptkb:senile_systemic_amyloidosis
ATTRwt amyloidosis
gptkbp:category amyloidosis
cardiac amyloidosis
systemic amyloidosis
gptkbp:causedBy deposition of wild-type transthyretin protein
transthyretin gene mutation
gptkbp:commonIn elderly men
gptkbp:complication gptkb:arrhythmias
congestive heart failure
restrictive cardiomyopathy
conduction system disease
gptkbp:depositsFoundIn ligaments
tendons
myocardium
peripheral nerves
gptkbp:diagnosedBy mass spectrometry
biopsy
cardiac MRI
technetium pyrophosphate scan
gptkbp:differentialDiagnosis hereditary ATTR amyloidosis
AL amyloidosis
gptkbp:firstDescribed late 20th century
gptkbp:hasBiomarker gptkb:troponin
gptkb:NT-proBNP
transthyretin levels
gptkbp:hasEpidemiology most common form of cardiac amyloidosis in elderly
gptkbp:hasGeneticCause none (wild-type, not mutated)
https://www.w3.org/2000/01/rdf-schema#label wild-type ATTR amyloidosis
gptkbp:ICD-10_code E85.1
gptkbp:involvesProtein gptkb:transthyretin
gptkbp:prevalence increases with age
gptkbp:prognosis variable, often poor if advanced
gptkbp:riskFactor male sex
advanced age
gptkbp:symptom gptkb:arrhythmia
gptkb:carpal_tunnel_syndrome
heart failure
peripheral neuropathy
gptkbp:treatment gptkb:patisiran
gptkb:tafamidis
supportive care
diuretics
heart failure medications
gptkbp:bfsParent gptkb:ATTR_amyloidosis
gptkbp:bfsLayer 8